Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure

Journal of Clinical Investigation

Volumn 104, Issue 10, 1999, Pages 1441-1447

  Smit, Johan W ^a   Huisman, Maarten T ^a   Van Tellingen, Olaf ^a   Wiltshire, Hugh R ^b   Schinkel, Alfred H ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AVERMECTIN; DIGOXIN; GLYCOPROTEIN P; PACLITAXEL; PLACENTA PROTEIN; SAQUINAVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PLACENTA BARRIER; CONTROLLED STUDY; DRUG TRANSPORT; GENOTYPE; MATERNAL PLASMA; MOUSE; NONHUMAN; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL;

EID: 0032701128     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI7963     Document Type: Article

References (40)

1. Juliano, R.L., and Ling, V. 1976. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta. 455:152-162.
2. Higgins, C.F. 1992. ABC transporters: from microorganisms to man. Annu. Rev: Cell Biol. 8:67-113.
3. Gottesman, M.M., and Pastan, I. 1993. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62:385-427.
4. Gros, P., Ben Neriah, Y.B., Croop, J.M., and Housman, D.E. 1986. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature. 323:728-731.
5. Devaulr, A., and Gros, P. 1990. Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities. Mol. Cell Biol. 10:1652-1663.
6. Thiebaut, F., et al. 1987. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Nat. Acad. Sci. USA. 84:7735-7738.
7. Song, R., Ikeguchi, M., Zhou, G., and Kuo, M.T. 1995. Identification and characterization of a hepatoma cell-specific enhancer in the mouse multidrug resistance mdr1b promoter. J. Biol. Chem. 270:25468-25474.
8. Croop, J.M., et al. 1989. The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol. Cell. Biol. 9:1346-1350.
9. Schurr, E., Raymond, M., Bell, J.C., and Gros, P. 1989. Characterization of the multidrug resistance protein expressed in cell clones stably transfected with the mouse mdr1 cDNA. Cancer Res. 49:2729-2733.
10. Schinkel, A.H., et al. 1994. Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 77:491-502.
11. Sparreboom, A., et al. 1997. Limited oral bio-availability and active epithelial excretion of paclicaxel (taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA. 94:2031-2035.
12. Kim, R.B., et al. 1998. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101:289-294.
13. Lankas, G.R., Wise, L.D., Cartwright, M.E., Pippert, T., and Umbenhauer, D.R. 1998. Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reprod. Toxicol. 12:457-463.
14. Umbenhauer, D.R., et al. 1997. Identification of a P-glycoprotein-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism. Toxicol. Appl. Pharmacol. 146:88-94.
15. Lankas, G.R., Cartwright, M.E., and Umbenhauer, D. 1997. P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. Toxicol. Appl. Pharmacol. 143:357-365.
16. Schinkel, A.H., et al. 1997. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug transporting) P-glycoproteins. Proc. Natl. Acid. Sci. USA. 94:4028-4033.
17. Mayer, U., et al. 1996. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr1a P-glycoprotein. Br. J. Pharmacol. 119:1038-1044.
18. Wiltshire, H.R., et al. 1998. The synthesis of labelled forms of saquinavir. J. Labelled Cpd. Radiopharm. 41:1103-1126.
19. Van Heeswijk, R.P., et al. 1998. Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir and saquinavir in human plasma by ion-pair high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. B. Biomed. Sci. Appl. 719:159-168.
20. Kim, A.E., Dintaman, J.M., Waddell, D.S., and Silverman, J.A. 1998. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J. Pharmacol. Exp. Ther. 286:1439-1445.
21. Lee, C.G., et al. 1998. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry. 37:3594-3601.
22. Mayer, U., et al. 1997. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J. Clin. Invest. 100:2430-2436.
23. Hyafil, F., Vergely, C., Du Vignaud, P., and Grand-Perret, T. 1993. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 53:4595-4602.
24. Wallstab, A., Koester, M., Böhme, M., and Keppler, D. 1999. Selective inhibition of MDR1P-glycoprotein-mediated transport by the acridone carboxamide derivative GG918. Br. J. Cancer. 79:1053-1060.
25. Cordon-Cardo, C., et al. 1989. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA. 86:695-698.
26. th nerves of guinea pig in relation to blood-nerve barrier sites. Neurosci. Lett. 232:41-44.
27. Jonker, J.W., et al. 1999. Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgesic drug. Br. J. Pharmacol. 127:43-50.
28. Nakamura, Y., et al. 1997. Function of P-glycoprotein expressed in placenta and mole. Biochem. Biophys. Res. Commun. 235:849-853.
29. Sugawara, I., et al. 1988. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res. 48:1926-1929.
30. Van Kalken, C.K., et al. 1992. Multidrug resistance gene (P-glycoprotein) expression in the human fetus. Am. J. Pathol. 141:1063-1072.
31. MacFarland, A., Abramovich, D.R., Ewen, S.W.B., and Pearson, C.K. 1994. Stage-specific distribution of P-glycoprotein in first-trimester and full-term human placenta. Histochem. J. 26:417-423.
32. Elbling, L., Berger, W., Rehberger, A., Waldhor, T., and Micksche, M. 1993. P-glycoprotein regulates chemosensitivity in early developmental stages of the mouse. FASEB J. 7:1499-1506.
33. De Lannoy, I.A.M., and Silverman, M. 1992. The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem. Biophys. Res. Commun. 189:551-557.
34. Tanigawara, Y., et al. 1992. Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1) J. Pharmacol. Exp. Ther. 263:840-845.
35. Schinkel, A.H., Wagenaar, E., van Deemter, L., Mol, C.A., and Borst, P. 1995. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyctosporin A. J. Clin. Invest. 96:1698-1705.
36. Newell, M.-L. 1998. Mechanism and timing of mother-to-child transmission of HIV-1. AIDS 12:831-837.
37. Casey, B.M., and Bawdon, R.E. 1998. Placental transfer of ritonavir with zidovudine in the ex vivo placental perfusion model. Am. J. Obstet. Gynecol. 179:758-761.
38. Tang-Wai, D.F., et al. 1995. Human (MDR1) and mouse (mdr1, mdr3) P-glycoproteins can be distinguished by their respective drug resistance profiles and sensitivity to modulators. Biochemistry. 34:32-39.
39. Merry, C., et al. 1997. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS. 11:F29-F33.
40. Hendrikse, N.H., et al. 1998. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br. J. Pharmacol. 124:1413-1418.